MCM
TPTX

Moore Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Moore Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$376K – 365
2019
Q3 		$376K Buy
+10,000
New +$435K 0.02% 265

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Moore Capital Management's TPTX Position: Q4 2019 in Review

Moore Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2019, closing a stake of 10,000 shares — an estimated $376K sold.

Moore Capital Management first reported a position in TPTX in Q3 2019 and held it in 1 quarter. The position peaked at $376K in Q3 2019. 120 funds tracked by Wall St. Rank hold TPTX as of Q4 2019.

  • Moore Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Moore Capital Management sold 10,000 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $376K.
  • Moore Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Moore Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $376K in Q3 2019.
  • 120 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Moore Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.